Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Shear-induced platelet aggregation.

J R O'Brien1

  • 1Central Laboratory, St Mary's Hospital, Portsmouth, Hampshire, UK.

Lancet (London, England)
|March 24, 1990
PubMed
Summary
This summary is machine-generated.

Platelet activation occurs via two pathways: one sensitive to aspirin involving thrombin and fibrinogen, and another, shear-induced pathway insensitive to aspirin, using von Willebrand factor. Targeting the shear-induced pathway may offer superior therapeutic benefits for thrombosis prevention.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Platelet Aggregation Tests and Thrombosis.

Journal of the Royal College of Physicians of London·2019
Same author

Superconductivity in the Einstein solid VAl(10.1).

Journal of physics. Condensed matter : an Institute of Physics journal·2012
Same author

Changes in platelet membranes possibly associated with platelet stickiness.

Nature·2010
Same author

Shear-induced Filter Blockage. A Population Based Appraisal of a Method for the Assessment of Platelet, White Cell and von Willebrand Factor Interactions.

Platelets·2010
Same author

Platelet Activation at High and Low Shear is Followed by Inactivation: The Clinical Relevance.

Platelets·2010
Same author

The rationale of the blood sedimentation rate.

The Practitioner·2010
Same journal

Convergence of metabolic risk in obesity and normal BMI: does risk disappear?

Lancet (London, England)·2026
Same journal

Metabolic traits in obesity and normal BMI in industrialised countries: a multi-country analysis of national population-based studies.

Lancet (London, England)·2026
Same journal

Safety and efficacy of mRNA vaccines: a mechanistic and public health perspective.

Lancet (London, England)·2026
Same journal

The US Ebola response and the future of global health leadership.

Lancet (London, England)·2026
Same journal

Daniel Mason: a tale of change.

Lancet (London, England)·2026
Same journal

The 2026 Wakley-Wu Lien Teh Prize Essay: why medicine, and why stay?

Lancet (London, England)·2026
See all related articles

Area of Science:

  • Biochemistry
  • Physiology
  • Pharmacology

Background:

  • Platelets play a crucial role in haemostasis and thrombosis.
  • Two distinct mechanisms of platelet activation are recognized.
  • Understanding these mechanisms is key to developing effective antithrombotic therapies.

Purpose of the Study:

  • To differentiate and characterize the two primary platelet activation pathways.
  • To investigate the ligands and sensitivities to aspirin for each pathway.
  • To evaluate the therapeutic potential of targeting shear-induced platelet activation.

Main Methods:

  • Analysis of platelet activation via glycoprotein IIb/IIIa receptor.
  • Identification of ligands: fibrinogen and von Willebrand factor.

Related Experiment Videos

  • Assessment of aspirin sensitivity for different activation stimuli.

    • Main Results:

    • Thrombin-mediated activation involves glycoprotein IIb/IIIa, fibrinogen, and is aspirin-sensitive via the cyclooxygenase pathway.
    • Shear-induced activation involves a different domain on glycoprotein IIb/IIIa, utilizes von Willebrand factor, and is aspirin-insensitive.
    • Shear-induced platelet activation appears to be a non-enzymatic process.

    Conclusions:

    • Platelet activation is mediated by at least two distinct pathways with different triggers and sensitivities.
    • Aspirin effectively inhibits thrombin-mediated, but not shear-induced, platelet activation.
    • Inhibiting shear-induced platelet activation may represent a more promising therapeutic strategy for preventing thrombosis than targeting aspirin-sensitive pathways.